DBV Technologies generates €166.7 million through the exercise of Warrants

DBV Technologies announced that it has raised €166.7 million in gross proceeds following the full exercise of the Warrants issued as part of its March 2025 financing. This additional financing is intended to support operations and commercial development of the VIASKIN® peanut allergy patch for children aged 4 to 7 in the United States, subject to approval. The exercise resulted in the issuance of 130.7 million new ordinary shares.

The financing is based on two bond issues in April 2025, offering the opportunity to subscribe to a total of 124,259,898 new shares. These funds are expected to cover DBV's operations over 12 months, particularly the launch of the VIASKIN® Peanut patch, which is subject to regulatory approval. The issuance has impacted the shareholding structure and shareholder participation, but has also strengthened the Company's consolidated equity.